NCT05882292View on ClinicalTrials.gov

c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Neoplasms
Interventions
DRUG

ABN401

ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.

Trial Locations (1)

03722

RECRUITING

minkyu Jung, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER